• Je něco špatně v tomto záznamu ?

Comparative efficacy and safety of alternatives to sodium valproate in the management of bipolar affective disorder in people of child-bearing age: a narrative review by the European Society of Clinical Pharmacy's mental health specialist interest group

I. Fitzgerald, I. Bayraktar, B. Eiden, R. Gittins, E. Magni, M. Humbert-Claude, LT. Molitschnig, P. Darm, A. Waksmundzka-Walczuk, N. Riesenhuber, M. Stuhec, I. Tašková, M. Hahn

. 2025 ; 47 (3) : 666-675. [pub] 20250428

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, přehledy, srovnávací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25015463

BACKGROUND: The European Medicines Agency has recommended a series of restrictions on the use of sodium valproate (valproate) following research linking its exposure in utero to adverse congenital and neurodevelopmental effects in offspring. Recent research has highlighted a potential increased risk of neurodevelopmental disorders in children born to males taking valproate prior to conception. Clinicians and patients require guidance regarding suitable alternatives. AIM: To provide an overview of suitable alternatives to valproate in the management of bipolar disorder. METHOD: A narrative review was conducted. Only medications with an established evidence base in managing different phases of bipolar disorder and endorsed within clinical practice guidelines were considered. Eligible guidelines included those (i) where recommendations were informed by a formal guideline development process and (ii) published in English within the last 15 years. REPROTOX® was chosen as the primary information source regarding reproductive safety of alternative medications. RESULTS: Of all second-generation antipsychotics, quetiapine should be considered a first-line alternative to valproate. Lithium has been associated with an increased risk of cardiac malformations, especially Ebstein anomaly, following in utero exposure. However, given its robust efficacy as an antimanic agent and the absolute risk of cardiac abnormalities being low, it's use can still be considered in individuals of child-bearing potential with appropriate monitoring. Carbamazepine treatment should be avoided due to concerns for teratogenicity. Although considered safe in pregnancy, lamotrigine is largely effective at preventing relapse of bipolar depression. Thus, lamotrigine offers limited clinical utility as an alternative to valproate. CONCLUSION: Specific recommendations are made regarding alternatives to valproate in managing bipolar disorder.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015463
003      
CZ-PrNML
005      
20250731091010.0
007      
ta
008      
250708s2025 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s11096-025-01919-x $2 doi
035    __
$a (PubMed)40293641
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Fitzgerald, Ita $u Pharmacy Department, St Patrick's Mental Health Services, St Patrick's University Hospital, Dublin 8, D08K7YW, Ireland. ifitzgerald@stpatricks.ie $u School of Pharmacy, University College Cork, Cork, Ireland. ifitzgerald@stpatricks.ie $1 https://orcid.org/0000000295708823
245    10
$a Comparative efficacy and safety of alternatives to sodium valproate in the management of bipolar affective disorder in people of child-bearing age: a narrative review by the European Society of Clinical Pharmacy's mental health specialist interest group / $c I. Fitzgerald, I. Bayraktar, B. Eiden, R. Gittins, E. Magni, M. Humbert-Claude, LT. Molitschnig, P. Darm, A. Waksmundzka-Walczuk, N. Riesenhuber, M. Stuhec, I. Tašková, M. Hahn
520    9_
$a BACKGROUND: The European Medicines Agency has recommended a series of restrictions on the use of sodium valproate (valproate) following research linking its exposure in utero to adverse congenital and neurodevelopmental effects in offspring. Recent research has highlighted a potential increased risk of neurodevelopmental disorders in children born to males taking valproate prior to conception. Clinicians and patients require guidance regarding suitable alternatives. AIM: To provide an overview of suitable alternatives to valproate in the management of bipolar disorder. METHOD: A narrative review was conducted. Only medications with an established evidence base in managing different phases of bipolar disorder and endorsed within clinical practice guidelines were considered. Eligible guidelines included those (i) where recommendations were informed by a formal guideline development process and (ii) published in English within the last 15 years. REPROTOX® was chosen as the primary information source regarding reproductive safety of alternative medications. RESULTS: Of all second-generation antipsychotics, quetiapine should be considered a first-line alternative to valproate. Lithium has been associated with an increased risk of cardiac malformations, especially Ebstein anomaly, following in utero exposure. However, given its robust efficacy as an antimanic agent and the absolute risk of cardiac abnormalities being low, it's use can still be considered in individuals of child-bearing potential with appropriate monitoring. Carbamazepine treatment should be avoided due to concerns for teratogenicity. Although considered safe in pregnancy, lamotrigine is largely effective at preventing relapse of bipolar depression. Thus, lamotrigine offers limited clinical utility as an alternative to valproate. CONCLUSION: Specific recommendations are made regarding alternatives to valproate in managing bipolar disorder.
650    _2
$a lidé $7 D006801
650    12
$a bipolární porucha $x farmakoterapie $7 D001714
650    12
$a kyselina valproová $x škodlivé účinky $x terapeutické užití $7 D014635
650    12
$a antimanika $x škodlivé účinky $x terapeutické užití $7 D018692
650    12
$a antipsychotika $x škodlivé účinky $x terapeutické užití $7 D014150
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a těhotenství $7 D011247
650    _2
$a výsledek terapie $7 D016896
650    12
$a management nemoci $7 D019468
651    _2
$a Evropa $x epidemiologie $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
655    _2
$a srovnávací studie $7 D003160
700    1_
$a Bayraktar, Izgi $u Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey
700    1_
$a Eiden, Birgit $u Pharmacy Department, Rheinhessen, Fachklinik Alzey, Alzey, Germany
700    1_
$a Gittins, Rosalind $u Aston School of Pharmacy, Aston University, Birmingham, UK
700    1_
$a Magni, Erica $u Pharmacy Department, ASP IMMeS e PAT, Milan, Italy
700    1_
$a Humbert-Claude, Marie $u Pharmacy of the Eastern Vaud Hospitals, Route du Vieux Séquoia 20, 1847, Rennaz, Switzerland
700    1_
$a Molitschnig, Lara-Turiya $u Pharmacy Department, Hospital of the Elisabethians Graz, Graz, Austria
700    1_
$a Darm, Paula $u Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital Frankfurt-Goethe University, Frankfurt, Germany
700    1_
$a Waksmundzka-Walczuk, Anna $u District Health Care Institute, Starachowice Hospital, Starachowice, Poland
700    1_
$a Riesenhuber, Nikolaus $u Pharmacy Department, Medical University of Vienna, Vienna, Austria
700    1_
$a Stuhec, Matej $u Faculty of Medicine, University of Maribor, Maribor, Slovenia $u Department of Clinical Pharmacy, Ormoz Psychiatric Hospital, Ormoz, Slovenia
700    1_
$a Tašková, Ivana $u Psychiatric Hospital Bohnice, Prague, Czech Republic $u Department of Applied Pharmacy, Faculty of Pharmacy, Masaryk University, Brno, Czech Republic
700    1_
$a Hahn, Martina $u Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital Frankfurt-Goethe University, Frankfurt, Germany $u Department of Mental Health, Varisano Hospital, Frankfurt, Germany $u Faculty of Pharmacy, Institute for Pharmacology and Clinical Pharmacy, Philipps-University Marburg, Marburg, Germany
773    0_
$w MED00180241 $t International journal of clinical pharmacy $x 2210-7711 $g Roč. 47, č. 3 (2025), s. 666-675
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40293641 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091005 $b ABA008
999    __
$a ok $b bmc $g 2366352 $s 1252588
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 47 $c 3 $d 666-675 $e 20250428 $i 2210-7711 $m International journal of clinical pharmacy $n Int J Clin Pharm $x MED00180241
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Možnosti archivace